MedTrace Logo

Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

NCT00587288 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2016-08-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness and safety of reslizumab in the treatment of subjects with poorly controlled asthma.

Conditions

Interventions

BIOLOGICAL

Reslizumab

OTHER

Saline

Sponsors & Collaborators

  • Cephalon

    collaborator INDUSTRY

  • Ception Therapeutics

    lead INDUSTRY

Principal Investigators

  • Sponsor's Medical Expert, MD · Cephalon (Ception)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00587288 on ClinicalTrials.gov